Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
55 participants
OBSERVATIONAL
2009-01-31
2015-01-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Adipose Tissue and Inflammation in Coronary Heart Disease
NCT02760914
Micro- and Macro-Circulation in Cardiac Surgery Patients
NCT05706545
Inflammatory Biomarkers Predict Pulmonary Outcomes in Coronary Artery Bypass Grafting
NCT01366469
Reference Values of Circulating Endothelial Progenitor Cells
NCT01918969
Cardiac Transplant Metabolomics With and Without Rejection
NCT05772442
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Traditional Framingham cardiovascular risk factors such as dyslipidemia and diabetes do not predict which grafts are at risk for failure. Therefore other variables such as hemodynamic factors or endothelial function may be important in identifying vulnerable vein grafts. The applicant has previously noted that vein grafts undergo dramatic geometric remodeling within the first month after implantation into the arterial circulation. This is partly driven by hemodynamic forces such as shear stress and is thought to be related to endothelial function. Shear stress is positively correlated with early (0-1 month) luminal enlargement. This adaptive response is important to maintain bypass graft patency. However, there is considerable amount of variability in this response unaccounted for by shear stress alone. The applicant has further shown that baseline systemic inflammation dampens the ability for adequate vein graft luminal expansion and therefore may uncouple the mechano-chemical signal transduction at the endothelial level. Therefore, this study will examine the relationship between circulating levels of inflammatory mediators and endothelial function in a cohort of patients undergoing lower extremity arterial reconstruction with autogenous vein.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Undergoing lower extremity (infrainguinal) bypass using autologous vein for the treatment of disabling claudication or critical limb ischemia secondary to chronic atherosclerotic occlusive disease
* Able to understand, give, and take part in the consent process
Exclusion Criteria
* Grafts employing prosthetic or other non-autologous vein material in any part (e.g. composite grafts). \[Patch angioplasty of inflow and outflow vessel permissible with any material\]
* Vasculitis, trauma, acute embolic disease as etiology of limb ischemia
* History of diagnosed hypercoagulable state
* Evidence of active infection - pneumonia, urinary tract, etc., requiring medical therapy
* Evidence of significant local sepsis in foot or limb prior to bypass
* Patients taking immunosuppressant medications (steroids, chemotherapeutic agents)
* Other concurrent significant illness within 30 days
* Non-English speakers
22 Years
89 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
University of California, San Francisco
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Warren J. Gasper, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of California, San Francisco
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
San Francisco Veterans Affairs Medical Center
San Francisco, California, United States
University of California, San Francisco
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HL92163-01
Identifier Type: -
Identifier Source: secondary_id
10-02338
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.